Publicaciones en colaboración con investigadores/as de Clínica Universitaria de Navarra (22)

2024

  1. Epigenetic-based differentiation therapy for Acute Myeloid Leukemia

    Nature Communications, Vol. 15, Núm. 1

2020

  1. Assessment of minimal residual disease by next generation sequencing in peripheral blood as a complementary tool for personalized transplant monitoring in myeloid neoplasms

    Journal of Clinical Medicine, Vol. 9, Núm. 12, pp. 1-20

  2. Plzf-rarα, npm1-rarα, and other acute promyelocytic leukemia variants: The pethema registry experience and systematic literature review

    Cancers, Vol. 12, Núm. 5

2015

  1. CIP2A high expression is a poor prognostic factor in normal karyotype acute myeloid leukemia

    Haematologica

2011

  1. NPM1 gene deletions in myelodysplastic syndromes with 5q- and complex karyotype

    Haematologica, Vol. 96, Núm. 5, pp. 784

2009

  1. Epigenetic silencing of the tumor suppressor microRNA Hsa-miR-124a regulates CDK6 expression and confers a poor prognosis in acute lymphoblastic leukemia

    Cancer Research, Vol. 69, Núm. 10, pp. 4443-4453

2008

  1. BCR-ABL1-induced expression of HSPA8 promotes cell survival in chronic myeloid leukaemia

    British Journal of Haematology, Vol. 142, Núm. 4, pp. 571-582

  2. Down-regulation of hsa-miR-10a in chronic myeloid leukemia CD34+ cells increases USF2-mediated cell growth

    Molecular Cancer Research, Vol. 6, Núm. 12, pp. 1830-1840

2007

  1. Multiple myeloma primary cells show a highly rearranged unbalanced genome with amplifications and homozygous deletions irrespective of the presence of immunoglobulin-related chromosome translocations

    Haematologica, Vol. 92, Núm. 6, pp. 795-802

  2. Simultaneous translocations of FGFR3/MMSET and CCND1 into two different IGH alleles in multiple myeloma: lack of concurrent activation of both proto-oncogenes

    Cancer Genetics and Cytogenetics, Vol. 175, Núm. 1, pp. 65.e1-65.e5

2006

  1. ASPP1, a common activator of TP53, is inactivated by aberrant methylation of its promoter in acute lymphoblastic leukemia

    Oncogene, Vol. 25, Núm. 13, pp. 1862-1870

  2. Abnormal methylation of the common PARK2 and PACRG promoter is associated with downregulation of gene expression in acute lymphoblastic leukemia and chronic myeloid leukemia

    International Journal of Cancer, Vol. 118, Núm. 8, pp. 1945-1953

  3. Downregulation of DBC1 expression in acute lymphoblastic leukaemia is mediated by aberrant methylation of its promoter

    British Journal of Haematology, Vol. 134, Núm. 2, pp. 137-144

2005

  1. Coexistence of different clonal populations harboring the b3a2 (p210) and e1a2 (p190) BCR-ABL1 fusion transcripts in chronic myelogenous leukemia resistant to imatinib

    Cancer Genetics and Cytogenetics, Vol. 160, Núm. 1, pp. 22-26

2004

  1. Chromosomal abnormalities clustering in multiple myeloma reveals cytogenetic subgroups with nonramdom acquisition of chromosomal changes [6]

    Leukemia

  2. NALP1 is a transcriptional target for cAMP-response-element-binding protein (CREB) in myeloid leukaemia cells

    Biochemical Journal, Vol. 384, Núm. 2, pp. 281-286

2003

  1. Lack of Bcr-Abl point mutations in chronic myeloid leukemia patients in chronic phase before imatinib treatment is not predictive of response

    Haematologica, Vol. 88, Núm. 12, pp. 1425-1426

  2. Secondary myelodysplastic syndrome after treatment for promyelocytic leukemia: Clinical and genetic features of two cases

    Cancer Genetics and Cytogenetics, Vol. 143, Núm. 2, pp. 178-181

1998

  1. Emergence of secondary acute leukemia in a patient treated for osteosarcoma: Implications of germline TP53 mutations

    Medical and Pediatric Oncology, Vol. 30, Núm. 3, pp. 165-169

1997

  1. Cytogenetic analysis of 280 patients with multiple myeloma and related disorders: Primary breakpoints and clinical correlations

    Genes Chromosomes and Cancer, Vol. 18, Núm. 2, pp. 84-93